Plexus Corporation
PLXS
$267.41
+1.28%
Plexus Corp is a leading provider of electronic manufacturing services (EMS), specializing in the design, manufacturing, and servicing of complex products for industries with demanding regulatory environments, including aerospace/defense, healthcare/life sciences, and industrial sectors. The company differentiates itself through its focus on high-complexity, high-reliability products and its integrated lifecycle solutions, from design and supply chain management to new product introduction and sustaining services. Currently, the investor narrative centers on Plexus's robust growth trajectory, driven by strong demand in its end markets, particularly in aerospace/defense and healthcare, and its ability to expand margins despite supply chain challenges. The stock has seen significant appreciation over the past year, reflecting confidence in its strategic positioning and operational execution.…
PLXS
Plexus Corporation
$267.41
PLXS 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Plexus Corporation's 12-month outlook, with a consensus price target around $305.75 and implied upside of +14.3% versus the current price.
Average Target
$305.75
0 analysts
Implied Upside
+14.3%
vs. current price
Analyst Count
—
covering this stock
Price Range
$275 - $330
Analyst target range
Plexus is covered by 4 analysts, with a consensus recommendation of 'Buy' and a mean recommendation score of 2.2 (where 1 is Strong Buy and 5 is Sell). The average target price is $293.25, implying a 16.7% upside from the current price of $251.34. The target range spans from $258.00 (low) to $330.00 (high), with the high target suggesting a 31.3% upside, reflecting optimism about continued growth and margin expansion. The low target implies only a 2.6% upside, indicating some analysts see limited near-term upside. Recent ratings actions have been predominantly positive, with Stifel upgrading from Hold to Buy in April 2026 and Needham and Benchmark maintaining Buy ratings, signaling growing confidence in the company's trajectory. The relatively narrow spread between the low and high targets (72 points) suggests moderate conviction among analysts, though the consensus leans bullish.
PLXS Technical Analysis
Plexus has exhibited a powerful long-term uptrend, with the stock price surging 97.13% over the past year, far outpacing the S&P 500's 18.19% gain. As of the latest close, the stock trades at $251.34, which is 81.9% of its 52-week range (low of $124.49, high of $307.06). This positioning near the upper end of the range suggests strong momentum, though it also implies the stock may be vulnerable to profit-taking after such a substantial run. The 52-week low was set in the past year, and the stock has more than doubled from that level, indicating a robust recovery and sustained investor interest.
Beta
0.90
0.90x market volatility
Max Drawdown
-20.8%
Largest decline past year
52-Week Range
$127-$307
Price range past year
Annual Return
+101.5%
Cumulative gain past year
| Period | PLXS Return | S&P 500 |
|---|---|---|
| 1m | +5.2% | +2.9% |
| 3m | +3.5% | +5.0% |
| 6m | +32.9% | +13.9% |
| 1y | +101.5% | +20.4% |
| ytd | +75.7% | +13.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
PLXS Fundamental Analysis
Plexus's revenue growth has been robust, with the most recent quarter (Q2 FY2026, ended April 4, 2026) reporting revenue of $1.1638 billion, a 18.73% year-over-year increase. This growth is part of a multi-quarter trend of accelerating revenue, with sequential increases from $1.0699 billion in Q1 FY2026 and $1.0584 billion in Q4 FY2025. The growth is broad-based across segments, with the Asia Pacific segment contributing the largest share at $651.96 million, followed by the Americas at $396.98 million and EMEA at $115.75 million. The company's focus on high-growth end markets like aerospace/defense and healthcare is driving this expansion, and the trend suggests continued momentum.
Quarterly Revenue
$1.2B
2026-04
Revenue YoY Growth
+18.7%
YoY Comparison
Gross Margin
10.2%
Latest Quarter
Free Cash Flow
$75793000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is PLXS Overvalued?
Given Plexus's positive net income, the most appropriate valuation metric is the price-to-earnings (PE) ratio. The trailing PE is 22.42x, while the forward PE is 25.34x, indicating that the market expects earnings to grow modestly in the coming year. The gap between trailing and forward PE suggests a slight deceleration in earnings growth, but the PEG ratio of 0.40 (based on expected EPS growth) implies the stock is undervalued relative to its growth prospects. This low PEG ratio is attractive, suggesting that the market may be underpricing Plexus's future earnings potential.
PE
22.4x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 12x~40x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.5x
Enterprise Value Multiple